Entities / Company
Quanterix (United States).
company in Lexington, United States
- Reports this week
- 0
- Active events
- 1
- Connections
- 41
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Gone quiet
No new reports in 90+ days-
Approval expands global access for biomarker detection for Quanterix.Speculative1 report
-
Exagen Inc. and Quanterix are companies operating in the Zacks Medical - Products industry.Some support2 reports
-
Quanterix agreed to a cooperation agreement to identify a new independent board member and agreed to customary standstill and voting commitments.Some support1 report
-
Quanterix acquired Akoya Biosciences in 2025, and the company presented at a conference in Boston.Some support6 reports1 development inside
-
Akoya Biosciences and Quanterix combine to create a high-margin, high-throughput business, with Masoud Toloue serving as CEO of Quanterix.Some support1 report
-
RSI (Q124832464) and Quanterix (Q30265448) were discussed regarding stock market indicators.Some support1 report
-
Quanterix appointed Masoud Toloue as CEO and expanded research capabilities in New York State, receiving a clinical lab permit.Some support1 report
-
Institutional owners hold a large stake in the company Quanterix.Some support1 report
No events began in the chosen period. Widen it, or reset.
Connections
The 1 strongest of 41, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Akoya Biosciences (United States) Structural
Akoya Biosciences was acquired by Quanterix, becoming a subsidiary and contributing to an integrated biomarker detection platform.
History
Events by the month they beganJune 2026
9 events- Trump's pledge to unleash oil and gas benefits stocks, involving Avery Dennison.
- Approval expands global access for biomarker detection for Quanterix.
- Exagen Inc. and Quanterix are companies operating in the Zacks Medical - Products industry.
- Quanterix agreed to a cooperation agreement to identify a new independent board member and agreed to customary standstill and voting commitments.
- Quanterix acquired Akoya Biosciences in 2025, and the company presented at a conference in Boston.
- Akoya Biosciences and Quanterix combine to create a high-margin, high-throughput business, with Masoud Toloue serving as CEO of Quanterix.
- RSI (Q124832464) and Quanterix (Q30265448) were discussed regarding stock market indicators.
- Quanterix appointed Masoud Toloue as CEO and expanded research capabilities in New York State, receiving a clinical lab permit.
- Institutional owners hold a large stake in the company Quanterix.